Cantor Fitzgerald Estimates Alector FY2026 Earnings

Alector, Inc. (NASDAQ:ALEC - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Alector in a report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will post earnings of ($1.69) per share for the year. The consensus estimate for Alector's current full-year earnings is ($1.88) per share.

A number of other brokerages also recently issued reports on ALEC. HC Wainwright upped their price objective on Alector from $7.00 to $10.00 and gave the company a "buy" rating in a research report on Friday, May 9th. Morgan Stanley restated an "underweight" rating and set a $1.50 price target (down previously from $3.00) on shares of Alector in a report on Friday, March 7th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, Alector has a consensus rating of "Hold" and an average price target of $4.00.

Alector Stock Up 10.4%

Alector stock traded up $0.15 during mid-day trading on Tuesday, reaching $1.59. 718,608 shares of the company's stock traded hands, compared to its average volume of 850,078. Alector has a 12-month low of $0.87 and a 12-month high of $6.78. The stock has a 50 day moving average of $1.17 and a two-hundred day moving average of $1.57. The company has a market cap of $158.99 million, a price-to-earnings ratio of -0.94 and a beta of 0.71.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Tower Research Capital LLC TRC boosted its position in Alector by 71.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 14,670 shares of the company's stock valued at $28,000 after buying an additional 6,096 shares during the period. ProShare Advisors LLC raised its stake in shares of Alector by 30.3% during the fourth quarter. ProShare Advisors LLC now owns 27,367 shares of the company's stock valued at $52,000 after acquiring an additional 6,367 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of Alector by 27.9% in the fourth quarter. SG Americas Securities LLC now owns 39,334 shares of the company's stock valued at $74,000 after purchasing an additional 8,581 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Alector by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 1,914,250 shares of the company's stock valued at $3,619,000 after purchasing an additional 10,308 shares during the period. Finally, Invesco Ltd. grew its stake in Alector by 27.7% in the fourth quarter. Invesco Ltd. now owns 47,985 shares of the company's stock worth $91,000 after purchasing an additional 10,405 shares in the last quarter. 85.83% of the stock is currently owned by institutional investors.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.